Prelude Therapeutics stock falls 9.9 percent despite FDA progress
Published on 09/23/2026 at 18:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Prelude Therapeutics stock was trading at USD 4.37 on Nasdaq at 12:41 p.m. ET on September 23, 2026, down 9.90 percent from the prior close of USD 4.85. The move comes as the clinical-stage biotechnology company advances PRT13722 toward human testing after a September 10 FDA clearance.
FDA clears breast cancer trial
Prelude Therapeutics said on September 10, 2026, that the FDA cleared its Investigational New Drug application for PRT13722, an oral KAT6A selective degrader for HR-positive and HER2-negative breast cancer. Patient enrollment in a Phase 1 study is expected to begin in the fourth quarter of 2026.
The program is an important development milestone, but the asset remains at the start of clinical testing. The planned study will evaluate PRT13722 as a single treatment and in combination with endocrine and targeted therapies.
Revenue rises as losses widen
Prelude reported Q2 2026 revenue of USD 5.7 million and a net loss of USD 13.9 million, according to Quartr. The loss increased 33.7 percent from the USD 10.4 million loss reported for Q1 2026, showing that development spending remains central to the company profile.
The same Q2 update cited USD 155.2 million in cash supporting clinical progress. That liquidity gives the pipeline more room to reach the planned fourth-quarter enrollment milestone, while the stock remains exposed to trial data and financing expectations.
Stock trades below yearly high
At USD 4.37, the stock was 36.0 percent below its 52-week high of USD 6.83 and 320.2 percent above its 52-week low of USD 1.04 on September 23, 2026. The intraday range was USD 4.32 to USD 4.87, placing the latest quote near the lower end of that session.
For investors, the key transition is from regulatory clearance to clinical execution. The next measurable checkpoint is the start of Phase 1 enrollment for PRT13722 in the fourth quarter of 2026.
Nasdaq trading reflects the risk
Prelude Therapeutics stock stood at USD 4.37 on Nasdaq at 12:41 p.m. ET on September 23, 2026. The USD 248.8 million market capitalization and the 9.90 percent daily decline underline how sharply early-stage biotechnology valuations can respond to development milestones.
Prelude Therapeutics key data
- Company: Prelude Therapeutics Incorporated
- Ticker: PRLD
- Trading venue: Nasdaq
- Price as of September 23, 2026, 12:41 p.m. ET: USD 4.37
- Market capitalization: USD 248,796,235 as of September 23, 2026
- 52-week range: USD 1.04-6.83 as of September 23, 2026
- Sector / Industry: Healthcare / Biotechnology
